Current Oncology, Free Full-Text
$ 9.50 · 5 (800) · In stock
Triple-negative breast cancer (TNBC) has a worse prognosis and remains the most challenging breast cancer subtype to treat. This is largely related to the heterogeneity of this disease and the lack of reliable oncological targets. In this review, we discuss the current standard-of-care treatment options for metastatic TNBC, including recent advances with the use of immunotherapy, PARP inhibitors and antibody-drug conjugates. This review also explores new agents and novel combinations arising in the field for the treatment of advanced TNBC.
New Cardio-Oncology Resources Page on - American College
Cancer Pathways Gonzaga University
A Multicentre, Randomised Trial Comparing Schedules Of, 44% OFF
Current Oncology, Free Full-Text
Current Oncology 2021 - Browse Issues
Current Oncology January 2023 - Browse Articles
National Comprehensive Cancer Network - Home
Current Oncology, Free Full-Text
Current Oncology, Free Full-Text
Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed